Knowledges and Use of Cannabidiol in Older Adults

Last updated: April 29, 2024
Sponsor: University Hospital, Toulouse
Overall Status: Active - Recruiting

Phase

N/A

Condition

Aging

Treatment

questionnaire

Clinical Study ID

NCT06094582
RC31/23/0494
2023-A02080-45
  • Ages 65-120
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The use of non-medical cannabidiol (CBD) has been growing recently in France and in the world, in young but also older adults. Few data are available on the use of cannabidiol in older adults. A better knowledge of the use of cannabidiol in older adults, and of their own knowledges of the molecule, is necessary to guide and follow the CBD uptake in this population and avoid potential adverse events.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • admitted to the frailty clinic, in Toulouse University Hospital during the recruitmentperiod.

Exclusion

Exclusion Criteria:

  • major cognitive disorder with Mini Mental State Examination <20
  • being under legal supervision or guardianship.

Study Design

Total Participants: 140
Treatment Group(s): 1
Primary Treatment: questionnaire
Phase:
Study Start date:
October 26, 2023
Estimated Completion Date:
May 31, 2024

Study Description

Cannabidiol may be used by patients because it may have beneficial pharmacological effects (including anxiolytic, analgesic, anti-inflammatories or antioxidant effects). Older adults aged 65 years and over, are more frequently at risk of multimorbidity and loss of autonomy, and may present with several symptoms like pain, anxiety, sleep disturbances, that may potentially respond to CBD. The molecule is often marketed as devoid of adverse effects. Nevertheless, with ageing, reduction in liver and kidney function, may have an impact on the metabolism and elimination of CBD and increase the risk of side-effect. As well, the risk of interaction with drugs frequently prescribed in older adults such as CYP3A4 inhibitors (verapamil, ketoconazole …), CYP3A4 inducers (phenytoin, carbamazepine, …) or CY92C19 inhibitors or inducers (fluoxetine …), may increase the risk of side effects. Our hypothesis is that the use of CBD has increased last years in older adults, but that they are insufficiently informed about this molecule. There is a need to assess the prevalence of CBD use in older adults in France, to assess the knowledges of CBD users about this substance, and to better characterize CBD users.

Connect with a study center

  • University Hospital Toulouse

    Toulouse, 31059
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.